Finally, CAFs mediated resistance to VEGF inhibitors in lymphoma xenografts models, by reactivating angiogenesis through platelet-derived growth factor C (PDGF-C) signaling, and PDGF-C targeting showed additive effects with anti-VEGFA antibodies [76]. This evidence concerns the gene PDGFC and lymphoma.